Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats
- 1 September 2007
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 293 (3), H1545-H1552
- https://doi.org/10.1152/ajpheart.00064.2007
Abstract
In this study, the cardioprotective effects of nitric oxide (NO)-aspirin, the nitroderivative of aspirin, were compared with those of aspirin in an anesthetized rat model of myocardial ischemia-reperfusion. Rats were given aspirin or NO-aspirin orally for 7 consecutive days preceding 25 min of myocardial ischemia followed by 48 h of reperfusion (MI/R). Treatment groups included vehicle (Tween 80), aspirin (30 mg·kg−1·day−1), and NO-aspirin (56 mg·kg−1·day−1). NO-aspirin, compared with aspirin, displayed remarkable cardioprotection in rats subjected to MI/R as determined by the mortality rate and infarct size. Mortality rates for vehicle ( n = 23), aspirin ( n = 22), and NO-aspirin groups ( n = 22) were 34.8, 27.3, and 18.2%, respectively. Infarct size of the vehicle group was 44.5 ± 2.7% of the left ventricle (LV). In contrast, infarct size of the LV decreased in the aspirin- and NO-aspirin-pretreated groups, 36.7 ± 1.8 and 22.9 ± 4.3%, respectively (both P < 0.05 compared with vehicle group; P < 0.05, NO-aspirin vs. aspirin ). Moreover, NO-aspirin also improved ischemiareperfusion-induced myocardial contractile dysfunction on postischemic LV developed pressure. In addition, NO-aspirin downregulated inducible NO synthase (iNOS; 0.37-fold, P < 0.01) and cyclooxygenase-2 (COX-2; 0.61-fold, P < 0.05) gene expression compared with the vehicle group after 48 h of reperfusion. Treatment with NG-nitro-l-arginine methyl ester (l-NAME; 20 mg/kg), a nonselective NOS inhibitor, aggravated myocardial damage in terms of mortality and infarct size but attenuated effects when coadministered with NO-aspirin. l-NAME administration did not alter the increase in iNOS and COX-2 expression but did reverse the NO-aspirin-induced inhibition of expression of the two genes. The beneficial effects of NO-aspirin appeared to be derived largely from the NO moiety, which attenuated myocardial injury to limit infarct size and better recovery of LV function following ischemia and reperfusion.This publication has 52 references indexed in Scilit:
- IL-1β inhibits intestinal smooth muscle proliferation in an organ culture system: involvement of COX-2 and iNOS induction in muscularis resident macrophagesAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2007
- Effects of purified herbal extract of Salvia miltiorrhiza on ischemic rat myocardium after acute myocardial infarctionLife Sciences, 2005
- Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological processInternational Journal of Cardiology, 2005
- Chemiluminescence and LC–MS/MS analyses for the study of nitric oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteersJournal of Pharmaceutical and Biomedical Analysis, 2004
- Nitric oxide in myocardial ischemia/reperfusion injuryCardiovascular Research, 2004
- PPARγ Inhibition of Cyclooxygenase-2, PGE 2 Synthase, and Inducible Nitric Oxide Synthase in Cardiac MyocytesHypertension, 2003
- NCX‐4016, a nitric oxide‐releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial functionThe FASEB Journal, 2002
- NCX4016 (NO‐aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigsBritish Journal of Pharmacology, 2002
- Identification of Regulated Genes in Rat Heart after Myocardial Infarction by Means of Differential mRNA Display.Japanese Heart Journal, 2000
- Production of Prostanoids and Nitric Oxide by Infarcted Heartin Situand the Effect of AspirinBiochemical and Biophysical Research Communications, 1999